Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irofulven + capecitabine + prednisone
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Irofulven + capecitabine + prednisone** is an experimental **combination regimen** investigated primarily for the treatment of **hormone-refractory (castration-resistant) prostate cancer** that has progressed after docetaxel.\n- **Irofulven** is a semisynthetic derivative of illudin S, functioning as a DNA alkylating agent, causing DNA damage and apoptosis in cancer cells.\n- **Capecitabine** is an oral prodrug of 5-fluorouracil (5-FU) that inhibits thymidylate synthase, blocking DNA synthesis and cell proliferation.\n- **Prednisone** is a synthetic glucocorticoid that exerts anti-inflammatory and immunosuppressive effects, often used in prostate cancer to reduce tumor-related symptoms and hormone-related inflammation.\nThis combination has been used in phase II trials comparing its efficacy and safety to other regimens in metastatic prostate cancer patients, notably after resistance to docetaxel[1][2][5].
- Other names
- irofulven + capecitabine + prednisone
02
Targets
GR (Glucocorticoid receptor)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on irofulven + capecitabine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irofulven + capecitabine + prednisone.